Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats
Reuters
Sep 13
<a href="https://laohu8.com/S/ZTS">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats
Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.